Skip to content
15% off your first order15% off your first order

PT-141 vs Kisspeptin-10

PT-141, also known as bremelanotide, and Kisspeptin-10 are both peptides studied in connection with desire and reproductive signaling, but they act at different points in the nervous and endocrine systems. Research describes PT-141 as an agonist at central melanocortin receptors, studied for influence on motivation and arousal circuits upstream of vascular response. Bremelanotide has received regulatory approval for hypoactive sexual desire disorder, and its safety profile has been reported across a clinical development program that included phase 3 trials. Kisspeptin-10 is described as acting on hypothalamic neurons to trigger GnRH release, initiating the hypothalamic-pituitary-gonadal cascade. Its literature is largely preclinical, spanning reproductive signaling, bone, cardiac, neuronal and metabolic models, and human safety data are limited.